Cytophage Technologies (TSXV:CYTO) Additional Paid-In Capital : C$0.00 Mil(As of Mar. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Cytophage Technologies Additional Paid-In Capital?

Cytophage Technologies Additional Paid-In Capital Historical Data

The historical data trend for Cytophage Technologies's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cytophage Technologies Additional Paid-In Capital Chart

Cytophage Technologies Annual Data

Trend

Dec21

Dec22

Dec23

Additional Paid-In Capital

Cytophage Technologies Quarterly Data
	Dec21	Sep22	Dec22	Mar23	Sep23	Dec23	Mar24
Additional Paid-In Capital	Get a 7-Day Free Trial			-	-	-	-	-

Cytophage Technologies Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital

(Issue Price

Par Value)

Shares Outstanding (Diluted Average)

Cytophage Technologies Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Cytophage Technologies's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Cytophage Technologies (TSXV:CYTO) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cytophage Technologies Ltd (TSXV:CYTO) » Definitions » Additional Paid-In Capital

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

Cytophage Technologies Ltd is a Canadian biotechnology company that uses molecular genetic techniques and synthetic biology to create effective bacteriophages to address bacterial challenges affecting animal health, human health, and food security. Bacteriophages are viruses that have evolved to specifically target and destroy strictly bacterial cells and are safe for humans, animals, and plants. To combat dangerous bacteria company generates phages to address specific bacterial infections, including strains resistant to antibiotics. It has also developed a 'phage-display' methodology to develop vaccine-like products using bacteriophages for a number of potential applications in human and animal health.